MARKET

IPSC

IPSC

Century Therapeutics, Inc.
NASDAQ
0.5437
+0.0437
+8.74%
After Hours: 0.5161 -0.0276 -5.08% 19:42 04/17 EDT
OPEN
0.5000
PREV CLOSE
0.5000
HIGH
0.5572
LOW
0.5000
VOLUME
657.55K
TURNOVER
--
52 WEEK HIGH
3.990
52 WEEK LOW
0.3418
MARKET CAP
46.78M
P/E (TTM)
-0.3378
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 2d ago
Weekly Report: what happened at IPSC last week (0407-0411)?
Weekly Report · 4d ago
Weekly Report: what happened at IPSC last week (0331-0404)?
Weekly Report · 04/07 09:03
Century Therapeutics Price Target Cut to $2.00/Share From $5.00 by HC Wainwright & Co.
Dow Jones · 04/03 11:09
Century Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 04/03 11:09
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $2
Benzinga · 04/03 10:59
Century Therapeutics price target lowered to $2 from $5 at H.C. Wainwright
TipRanks · 04/03 10:16
CENTURY THERAPEUTICS, INC. <IPSC.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $2 FROM $5
Reuters · 04/03 10:06
More
About IPSC
More
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
Recently
Symbol
Price
%Change

Webull offers Century Therapeutics Inc stock information, including NASDAQ: IPSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPSC stock methods without spending real money on the virtual paper trading platform.